MEDIOCON INC – Ladostigil Tartrate is the tartrate salt of Ladostigil (TV-3326), an investigational multifunctional compound developed for potential use in neurodegenerative disorders. Ladostigil combines monoamine oxidase (MAO) inhibitory activity with cholinesterase-inhibitory activity and has been investigated particularly in the context of Alzheimer's disease and related neurodegenerative conditions.
Ladostigil Tartrate is a salt form containing two molecules of Ladostigil and one molecule of tartaric acid. The compound is identified by CAS 209394-46-7. The molecular formula for the complete tartrate composition is 2C₁₆H₂₀N₂O₂·C₄H₆O₆, with a molecular weight of approximately 694.77 g/mol.
Product Name: Ladostigil Tartrate
CAS Number: 209394-46-7
Molecular Formula: 2C₁₆H₂₀N₂O₂·C₄H₆O₆
Molecular Weight: Approximately 694.77 g/mol
Chemical Class: Carbamate / MAO and cholinesterase inhibitor
Development Code: TV-3326 / TV3326
Parent Compound: Ladostigil
Parent Compound CAS: 209394-27-4
NCATS identifies the tartrate substance with a molecular formula of 2C₁₆H₂₀N₂O₂·C₄H₆O₆ and molecular weight 694.7712 g/mol.
Ladostigil was designed as a multifunctional neuroprotective compound with activity involving monoamine oxidase (MAO) and cholinesterase pathways. These mechanisms were investigated for their potential to address multiple biochemical pathways involved in neurodegenerative disorders.
Ladostigil Tartrate is an investigational compound, and it should not be presented as an approved treatment for Alzheimer's disease or another neurological disorder.
MEDIOCON INC focuses on supplying pharmaceutical and specialty chemical ingredients with emphasis on quality, consistency, technical documentation and reliable supply.
Ladostigil Tartrate quality evaluation may include identification, assay, chromatographic purity, related substances, residual solvents, water content, residue on ignition and other parameters according to the applicable product specification.
The exact analytical acceptance criteria should be confirmed against the current approved specification and batch-specific Certificate of Analysis.
Ladostigil Tartrate has been investigated in pharmaceutical research involving neurodegenerative disorders, particularly Alzheimer's disease and related cognitive disorders.
Because Ladostigil remains an investigational compound, the product should be positioned for research and development applications rather than as an approved therapeutic API.
Commercial research-product information describes Ladostigil Tartrate as a white to beige powder. Sigma-Aldrich reports the material in powder form, with a reported research-product assay of ≥98% by HPLC.
Appearance: White to beige powder
Product availability, packaging configuration, Certificate of Analysis (COA), Safety Data Sheet (SDS/MSDS), technical specifications and other documentation should be confirmed with MEDIOCON INC according to the intended application and customer requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to beige powder |
| Assay (HPLC) | ≥98.0% |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Ladostigil Tartrate API Manufacturer and Supplier in India (CAS 209394-46-7) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Ladostigil Tartrate API Manufacturer and Supplier in India is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing before release with a Certificate of Analysis.
Export Markets
Quality & Compliance